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Abstract
Cerebral reperfusion and arterial recanalization are radiological features of the effectiveness of thrombolysis in acute ischemic
stroke (AIS) patients. Here, an investigation of the prognostic role of early recanalization/reperfusion on clinical outcome was
performed. In AIS patients (n = 55), baseline computerized tomography (CT) was performed ≤ 8 h from symptom onset, whereas
CT determination of reperfusion/recanalization was assessed at 24 h. Multiple linear and logistic regression models were used to
correlate reperfusion/recanalization with radiological (i.e., hemorrhagic transformation, ischemic core, and penumbra volumes)
and clinical outcomes (assessed as National Institutes of Health Stroke Scale [NIHSS] reduction ≥ 8 points or a NIHSS ≤ 1 at 24 h
and as modified Rankin Scale [mRS] < 2 at 90 days). At 24 h, patients achieving radiological reperfusion were n = 24, while the
non-reperfused were n = 31. Among non-reperfused, n = 15 patients were recanalized. Radiological reperfusion vs. recanaliza-
tion was also confirmed by early increased levels of circulating inflammatory biomarkers (i.e., serum osteopontin). In multivar-
iate analysis, ischemic lesion volume reduction was associated with both recanalization (β = 0.265; p = 0.014) and reperfusion
(β = 0.461; p < 0.001), but only reperfusion was independently associated with final infarct volume (β = − 0.333; p = 0.007).
Only radiological reperfusion at 24 h predicted good clinical response at day 1 (adjusted OR 16.054 [1.423–181.158]; p = 0.025)
and 90-day good functional outcome (adjusted OR 25.801 [1.483–448.840]; p = 0.026). At ROC curve analysis the AUC of
reperfusion was 0.777 (p < 0.001) for the good clinical response at 24 h and 0.792 (p < 0.001) for 90-day clinical outcome.
Twenty-four-hour radiological reperfusion assessed by CT is associated with good clinical response on day 1 and good functional
outcome on day 90 in patients with ischemic stroke.
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Introduction
The early pharmacological or mechanical restoration of the
blood flow in the ischemic brain is recommended to treat acute
ischemic stroke (AIS) [1, 2]. The effectiveness of
thrombolysis is mainly driven by the establishment of early
recanalization and/or reperfusion [3]. Although they are close-
ly related, these pathophysiological conditions can be radio-
logically identified. For instance, thrombolysis may fail to
induce recanalization [4, 5], but reperfusion may be
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maintained by collateral circulation. In turn, successful recan-
alization does not consistently lead to reperfusion in case of
distal thrombus embolization [6] or no-reflow phenomenon
[7]. Despite these pathophysiological aspects, the term
Brecanalization^ and Breperfusion^ have been long-time used
interchangeably [8]. Nowadays, advances in imaging methods
have been applied to discriminate these entities. In addition, it
is now possible to routinely visualize the ischemic core, the
penumbral tissue, and the state of collateral blood supply.
Recently, the clinical benefit of recanalization achieved by
endovascular treatment was demonstrated in seven clinical
trials, whereas the prognostic relevance of reperfusion in
predicting improved clinical and radiological outcome was
reported in some of these and other clinical trials [9–12].
This study, enrolling patients with AIS and undergoing serial
examination with computerized tomography (CT), has been
designed to compare the prognostic value of reperfusion vs.
recanalization after an AIS. Whereas long-term (day 90) good
functional outcome was set as primary endpoint, we have also
planned to investigate potential correlations between reperfu-
sion and serum inflammatory biomarkers.
Methods
Patients Selection and Clinical Assessment
We retrospectively analyzed clinical and radiological data from
n = 55 consecutively AIS patients admitted to the Neuroscience
Department of Ferrara University Hospital during the period
from April 2016 to December 2017. All patients were treated
according to the current guidelines [13, 14]. Inclusion criteria
were: (i) presentation at the hospital within 8 h from symptom
onset; (ii) baseline and follow-up confirmation of a large vessel
anterior AIS based on CT findings represented by the absence of
intracranial hemorrhage on non-contrast CT (NCCT) at admis-
sion, the presence of a territorial hypoperfused area on CT per-
fusion (CTP) at onset and the presence of a territorial
hypoattenuated area on NCCT at 24 h; (iii) baseline and
follow-up CT imaging carried out at established time points after
symptom onset (NCCT, CT angiography [CTA], and CTP at
admission, NCCT, CTA, and CTP at day 1 and NCCT at day
90). Exclusion criteria included the detection of brain stem infarct
or intracerebral hemorrhage at admission NCCT, the inability to
complete multimodal CT protocol at baseline and follow-up,
history of strokes with residual deficit; contraindications to iodin-
ated contrast agent, pregnancy, age < 18 years, clinical instability
and/or poor quality of CT acquisition due to motion artifacts.
Lacunar AIS were also excluded, due to the low sensitivity of
CTP in detecting them [15, 16]. To select a more homogenous
population, we further excluded minor strokes (defined by a
NIHSS < 4) as well as patients receiving intra-arterial thrombol-
ysis and mechanical thrombectomy. As previously reported [17],
we further excluded patients with lacunar/undetermined or pos-
terior circulation stroke, NIHSS < 4 at enrollment and those re-
ceiving intra-arterial thrombolytic therapy as well. Type of reper-
fusion therapy (if any) was recorded. The Trial of ORG 10172 in
Acute Stroke Treatment (TOAST) criteria were used to catego-
rize AIS subtypes. [18], whereas the National Institutes of Health
Stroke Scale (NIHSS) was used to score the disease severity at
onset, day 1, and day 90 after AIS [19]. The Local Ethics
Committee approved this study, in accordance with the guide-
lines of the Declaration of Helsinki. All patients gave informed
consent before entering in the study.
Study Endpoint and Power Estimation
The primary endpoint was to determine whether the occur-
rence of radiological reperfusion might predict long-term
(day 90) good functional outcome, defined as a modified
Rankin scale (mRS) at day 90 < 2 [17, 20, 21]. The sample
size was computed based on an expected prevalence of com-
plete reperfusion of 45%, taking into account a prevalence of
good functional outcome of 65% and a minimum of six-fold
increased incidence in reperfused patients [17, 21]. According
to our power calculation for two proportion comparison, the
minimum sample size requested to detect a six-fold increase in
the incidence of good functional outcome with a power of
80% and with a two-sided alpha error of 5% was of 12 pa-
tients. As secondary endpoint, we investigated the ability of
reperfusion to predict early favorable clinical response, de-
fined as a reduction of ≥ 8 points on the NIHSS [17] during
the first day after AIS, and the occurrence of haemorrhagic
transformation during the first 7 days after AIS. Finally, po-
tential correlations between reperfusion and serum biomarkers
of inflammation has been explored. Two blinded independent
investigators adjudicated the study endpoints.
Imaging Acquisition Protocol
All images were conducted on 64-slice scanners and included
(i) NCCT carried out from the skull base to the vertex; (ii)
CTA performed from the carotid bifurcation to vertex; (iii)
CTP that covered a total of 4 cm from the basal ganglia to
the lateral ventricles. CTP studies were obtained with a dy-
namic first-pass bolus-tracking methodology according to a
one-phase imaging protocol consisting of an acquisition of
50-s continuous (cine) scans, which started 5 s after the auto-
matic injection of 40 ml of non-ionic contrast agent at the rate
of 4 ml/s.
Imaging Processing and Analysis
According to EXTEND-IA trial [22], the severity of arterial
occlusion was judged on CTA at onset using a modified ver-
sion of the Thrombolysis in Myocardial Infarction (TIMI)
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grading system: complete occlusion (TIMI score = 0–1); par-
tial occlusion (TIMI score = 2); no occlusion (TIMI score = 3).
Patients with TIMI score ranging between 0 and 1 were cate-
gorized as occluded, whereas a TIMI score of 2 and 3 defined
the not occluded ones. The site of occlusion was assessed as
previously indicated [23]. All CTP scans were assessed using
a commercially available delay-sensitive deconvolution soft-
ware (CT Perfusion 3, GE Healthcare, Waukesha, WI). For
each CTP scan, time-density curves for the arterial input func-
tion and venous output functions were obtained from the an-
terior cerebral artery and superior sagittal sinus, respectively.
The AIF was corrected for partial volume averaging using the
VOF-TDC. Cerebral blood flow (CBF), cerebral blood vol-
ume (CBV), and mean-transit-time (MTT) CTP maps were
generated for each patient by deconvolution of tissue TDCs
and the AIF. CBF, CBV, and MTT values were expressed in
ml/min/100 g, ml/100 g, and seconds, respectively. Large
blood vessels were automatically excluded from calculation
by the software. Color coded functional CTP map scales were
set at 0–100 ml/min/100 g for CBF, 0–8 ml/100 g for CBV,
and 0–20 s for MTT. After identification by visual inspection
on MTT and CBV maps, three different regions of interest
(ROIs) were drawn freehand by two neuroradiologists (A.B.
and E.F., with 5- and 20-year experience, respectively) on
every section in which they were visible according to the
classical CTP mismatchmodel [24]: (i) MTT lesion indicating
total hypoperfusion; (ii) CBV lesion referring to infarct core;
(iii) MTT-CBV lesion representing ischemic penumbra
(Fig. 1). This last ROI was outlined on MMT maps where
the ROI corresponding to CBV defect were automatically
superimposed. Discrepancies between readers were resolved
by consensus adjudication. The sum of these lesion areas was
thenmultiplied by slice thickness to obtain core and penumbra
(CTP MTT-CBV mismatch) volumes, respectively. Final in-
farct volume was measured on follow-up NCCT at 3 months
after symptom onset with a multi-slice planimetric method by
summation of the hypodense areas, manually traced on each
slice in which they were detectable, multiplied by slice thick-
ness [25]. The type of HTwas recorded by NCCT at 24 h and
at 7 days post ictus. In agreement with EXTEND-IA trial [22],
recanalization was scored on CTA at 24 h with an adaptation
of the TIMI grading system: persistent occlusion (TIMI
score = 0–1); partial recanalization (TIMI score = 2); full re-
canalization (TIMI score = 3). Patients with TIMI score rang-
ing from 2 to 3 were considered as recanalized, whereas pa-
tients with TIMI score of 0 and 1 were classified as not
recanalized. All patients not occluded on CTA at admission
had a TIMI score of 3 at 24 h-CTA and therefore, were con-
sidered as recanalized. Radiological reperfusion was evaluat-
ed by reperfusion index that measures the percentage reduc-
tion of baseline MTT lesion at 24 h. For this purpose, visually
identified MTT defect volume was obtained by a manual
multi-slice planimetric method at admission and at 24 h
[26]. Patients with a reperfusion index > 75%were considered
as reperfused. Reduction of the ischemic volume was
expressed as the difference between total hypoperfusion vol-
umes at admission (baseline) and at 24 h.
Blood Collection and Quantification
Blood samples were collected at different time points using a
butterfly to reduce membrane shear stress and then drawn in
tubes to obtain serum. Samples were collected at baseline and
at day 1 after AIS. Hematology parameters and blood chemistry,
including plasma glucose, triglycerides, total cholesterol, high-
density lipoprotein, and low-density lipoprotein cholesterol (to
assess dyslipidemia) were measured by routine auto-analyzer.
Measurement of a Serum Biomarker Associated
with Reperfusion
Serum osteopontin (OPN), a biomarker associated with cere-
bral reperfusion [27, 28], were measured by colorimetric
enzyme-linked immunosorbent assay (ELISA), following
Fig. 1 Color coded functional CT perfusion map. After identification by
visual inspection on mean-transit-time (MTT) and cerebral blood volume
(CBV)maps, 3 different regions of interest were drawn freehand on every
section according to the classical CTP mismatch model: a MTT lesion
indicating total hypoperfusion; b CBV lesion referring to infarct core; c
MTT-CBV lesion representing ischemic penumbra
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manufacturer’s instructions (R&D Systems, Minneapolis,
MN). The limits of detection for OPN was 62.5 pg/ml.
Mean intra- and inter-assay coefficients of variation (CV)
were below 8% for all markers [29].
Statistical Analysis
Analyses were performed with IBM SPSS Statistics for
Windows, Version 23.0 (IBM CO., Armonk, NY).
Categorical data are presented as relative and absolute fre-
quencies. Continuous variables were expressed as median
and interquartile range (IQR) as the normality assumption
was not demonstrated. Difference between two time points
was presented as delta (Δ). Intergroup comparisons were
drawn by Fisher’s exact test and Mann-Whitney U test, as
appropriate. Conversely, the dichotomized classification of
reperfusion and recanalization was compared by McNemar
test instead comparison between paired sample was drawn
byWilcoxon rank sum test ranked. Multiple linear regressions
were performed to model the lesion growth and final infarct
volumes with the recanalization and reperfusion. Multivariate
logistic regression was used to evaluate the predictive role of
recanalization and reperfusion toward good clinical response
and good functional outcome. Finally, the prognostic ability
was assessed in a post-hoc manner based upon receiver oper-
ator characteristic (ROC) curve (MedCalc 12.5, MedCalc
Software, Ostend, Belgium). The area under the curve
(AUC) was given with 95% confidence interval (CI). For all




Baseline clinical characteristics of the whole cohort (n = 55)
are listed in Table 1. Patients’ median age was 69 years (55–
76), with a slight prevalence of hypertension (58.2%). In most
cases the time window between symptom onset and CT study
performed was less than 3 h (81.8%), thus accounting for a
high rate of reperfusion therapy with r-tPA (70.9%). More
precisely, in our study population, 49/55 (89.1%) patients
were treated (n = 39 with intravenous thrombolysis with r-
tPA and n = 10 with mechanical thrombectomy), whereas 6/
55 (10.9%) did not receive any therapy due to the presence of
hypodensity > 1/3 cerebral hemisphere, as indicated by
ASPECTS ≤ 7, on admission NCCT (n = 3), and the current
use of anticoagulant with INR > 1.7 (n = 3). At day 1 after
AIS, reperfusion was present in 24 patients (43.6%)
(Table 2). In 15 patients (27.3%), there was a pattern charac-
terized by recanalization without reperfusion (Table 2).
Conversely, no patients had reperfusion without
recanalization, whereas in 24 patients (43.6%) both reperfu-
sion and recanalization were observed. A McNemar test on
the dichotomized classification of reperfusion and recanaliza-
tion confirmed a significant discrepancy between these two
parameters (p < 0.001) (Table 2).
Reperfusion and Recanalization Weakly Influences
Inflammatory Biomarkers and Radiological Features
of Cerebral Injury
Ischemic core and penumbra volumes did not differ in patients
categorized as recanalized vs. non-recanalized and reperfused
Table 1 Clinical characteristics of study population (n = 55) at
admission
Demographic
Age, years (IQR) 69 (55–76)
Male, no. (%) 29 (52.7)
Hypertension, no. (%) 32 (58.2)
Atrial fibrillation, no. (%) 23 (43.4)
Active smokers, no. (%) 18 (33.3)
Previous smokers, no. (%) 5 (9.1)
Diabetes, no. (%) 4 (7.3)
Dyslipidemia, no. (%) 13(23.6)
Biochemical
Total WBC#, no. × 109 (IQR) 7.91 (6.70–9.54)
Neutrophil count, no. × 109 (IQR) 4.83 (3.71–6.74)
Lymphocyte count, no. × 109 (IQR) 2.1 (1.53–2.58)
Serum glycaemia, mg/dL (IQR) 112 (97–143)
INR*, no. (IQR) 1.09 (1.02–1.19)
Clinical/ radiological
Time window to CT†
0–3 h, no. (%) 45 (81.8)
3–6 h, no. (%) 9 (16.4)
6–8 h, no. (%) 1 (1.8)
TOAST‡ classification
Atherothrombotic, no. (%) 32 (58.2)
Cardio-embolic, no. (%) 23 (43.4)
Intravenous r-tPA§, no. (%) 39 (70.9)
NIHSS|| 10 (7–14)
Total hypoperfused volume, ml (IQR) 88.03 (36.48–129.18)
Ischemic core volume, ml (IQR) 5.74 (0.51–17.18)
Ischemic penumbra, ml (IQR) 59.63 (27.04–102.32)
Data are expressed as median (interquartile range [IQR]) or number [no.]
(percentages [%])
#WBC: white blood cells
*INR: international normalized ratio
†CT: computerized tomography
‡TOAST: Trial of Org 10172 in Acute Stroke Treatment
§ r-tPA: recombinant tissue plasminogen activation
|| NIHSS: National Institutes of Health Stroke Scale
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vs. non-reperfused (Fig. 2a–c). Conversely, reperfusion deter-
mined a great reduction of the ischemic volume during the
first day after AIS (Δ baseline-day 1, 78.59 vs. 14.59 ml; p
< 0.001). A lesser but significant benefit was also observed in
the group of recanalized patients (Δ baseline-day 1, 37.95 vs.
13.30 ml; p = 0.025). OPN was tested as a known circulating
mediators increased after cerebral reperfusion [27, 28].
Noteworthy, when non-reperfused and reperfused patients
were analyzed separately, no difference was shown in demo-
graphic, biochemical and clinical/radiological parameters
(Table 3). Whereas no difference was observed at baseline, a
significant increase was observed the day after AIS (p =
0.002), thus determining a significant difference among the
two study groups (p = 0.004) (Fig. 3). Multilinear regression
analysis further confirmed an independent association of vol-
ume lesion reduction at day 1 with both recanalization (29.425
[6.271–52.580]; β = 0.265; p = 0.014) and reperfusion (B
46.803 [95% CI 29.138–64.469]; β = 0.461; p < 0.001)
(Table 4). However, only the reperfusion was independently
associated with final infarct volume at day 90 after AIS (B −
54.236 [95% CI 93.203- -15.270]; β = −0.333; p = 0.007)
(Table 4).
Table 2 Radiological characteristic at day 1
p value
Reperfusion, n (%) 24 (43.6)
Recanalization, n (%) 39 (70.9)
Reperfusion vs. recanalization < 0.001




Reperfusion without recanalization, n (%) 0 (0.0)
Reperfusion and recanalization, n (%) 24 (43.6)
Data are expressed as median (interquartile range [IQR]) or number [no.]












































































































































representative plots of the impact
of recanalization/reperfusion of
radiological findings. The values
of ischemic core volume (a),
ischemic penumbra (b), and
difference (Δ) in hypoperfused
volume between onset at 24 h (c)
are represented in non-
recanalized/recanalized and non-
reperfused/reperfused patients
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Reperfusion at 24 h Is a Strong Predictor of Good
Outcome After an AIS
Reperfusion, but not recanalization, was able to predict good
clinical response at 24 h also after adjustments for age, gender,
glycaemia, time window to CT, intravenous thrombolysis,
NIHSS, ischemic core and penumbra volumes at onset (OR
16.054 [1.423–181.158]; p = 0.025) (Table 5). Though non-
significant, reperfusion shown a trend toward the prediction of
hemorrhagic transformation during the first 7 day after AIS
(adjusted OR 0.153 [0.022–1.047]; p = 0.056) (Table 5).
However, the most relevant result was the predictive ability
of reperfusion toward 90-day good functional outcome,
assessed by mRS (adjusted OR 25.801 [1.483–448.840];
p = 0.026) (Table 5). ROC curve analysis, further character-
ized the predictive ability of reperfusion by showing an AUC
of 0.777 (sensitivity 88.89%, specificity 64.86%; p < 0.001)
and 0.792 (sensitivity 88.89%, specificity 75.68%; p < 0.001)
for the good clinical response and good long-term clinical
outcome, respectively (Fig. 4).
Discussion
In this study, reperfusion at 24 h after AIS consistently over-
came recanalization in predicting radiological evolution of
ischemic lesion and clinical outcomes. Indeed, patients with
MTT reperfusion index > 75% experienced a greater
Table 3 Clinical differences
among non-reperfused and
reperfused patients at baseline
Non-reperfused (n = 31) Reperfused (n = 24) p value
Demographic
Age, years (IQR) 67 (58–76) 71 (46–78) 0.939
Male, no (%) 17 (54.8) 12 (50.0) 0.789
Hypertension, no. (%) 19 (61.3) 13 (54.2) 0.783
Atrial fibrillation, no. (%) 12 (38.7) 11 (45.8) 0.783
Active smokers, no. (%) 13 (41.9) 5 (21.7) 0.151
Previous smokers, no. (%) 3 (9.7) 2 (8.3) 1.000
Diabetes, no. (%) 3 (9.7) 1 (4.2) 0.624
Dyslipidemia, no (%) 10 (32.3) 3 (12.59 0.116
Biochemical
Total WBC#, no. × 109 (IQR) 7.91 (6.99–10.01) 7.8 (6.26–9.01) 0.396
Neutrophil count, no. × 109 (IQR) 5.11 (3.69–7.36) 4.45 (3.74–6.42) 0.665
Lymphocyte count, no. × 109 (IQR) 2.1 (1.65–2.74) 2.13 (1.18–2.58) 0.773
Serum glycaemia, mg/dL (IQR) 116 (103–166) 107 (91–130) 0.096
INR*, no. (IQR) 1.08 (1.01–1.13) 1.13 (1.02–1.28) 0.098
Clinical/ radiological
Time window to CT† 0.214
0–3 h, no. (%) 24 (77.4) 21 (87.5)
3–6 h, no. (%) 7 (16.422.6) 2 (8.3)
6–8 h, no. (%) 0 (0.0) 1 (4.2)
TOAST‡ classification
Atherothrombotic, no. (%) 19 (61.3) 13 (54.2)
Cardio-embolic, no. (%) 12 (38.7) 11 (45.8) 0.783
Intravenous r-tPA§, no (%) 21 (67.7) 18 (75.0) 0.765
NIHSS|| 11 (7–20) 10 (7–14) 0.208
Comparison were drawn byMann-Whitney U test, Fisher’s exact test or Kruskal-Wallis test, as appropriate. Data
are expressed as median (interquartile range [IQR]) or number [no.] (percentages [%])
#WBC: white blood cells
*INR: international normalized ratio
†CT: computerized tomography
‡TOAST: Trial of Org 10172 in Acute Stroke Treatment
§ r-tPA: recombinant tissue plasminogen activation
|| NIHSS: National Institutes of Health Stroke Scale



























representative plots of the
modification in circulation
osteopontin (OPN). Circulating
OPN levels were quantified at
baseline and after 1 day from
stroke onset. Intergroup
comparisons and overtime change
were assayed
Table 4 Multiple linear
regression for predicting the
reduction of ischemic lesion
volume at day 1 and the final
infarct at day 90
B (95% CI) β p value
Volume lesion reduction
Age − 0.069 (− 0.640 to 0.502) − 0.019 0.809
Gender, male 7.361 (− 8.481 to 23.202) 0.073 0.354
Glycemia − 0.105 (− 0.324 to 0.115) 0.109 0.341
Time window to CT# − 4.948 (− 23.525 to 13.628) − 0.044 0.594
Intravenous r-tPA* − 2.095 (− 21.594 to 17.404) − 0.019 0.830
NIHSS† at onset − 0.139 (− 1.753 to 1.475) − 0.016 0.863
Ischemic core volume 0.554 (0.290 to 0.819) 0.334 < 0.001
Ischemic penumbra 0.663 (0.496 to 0.830) 0.587 < 0.001
Reperfusion at day 1 46.803 (29.138 to 64.469) 0.461 < 0.001
Recanalization at day 1 29.425 (6.271 to 52.580) 0.265 0.014
Final infarct volume
Age − 0.851 (− 41.309 to 191.681) − 0.142 0.180
Gender, male − 22.466 (− 57.409 to 12.477) − 0.139 0.202
Glycemia − 0.058 (− 0.542 to 0.426) − 0.027 0.809
Time window to CT 42.518 (1.540 to 893.945) 0.233 0.042
Intravenous r-tPA 22.079 (− 20.931 to 65.090) 0.124 0.307
NIHSS at onset 2.289 (− 1.271 to 5.849) 0.163 0.202
Ischemic core volume 1.270 (0.687 to 1.854) 0.476 < 0.001
Ischemic penumbra − 0.060 (0.428 to 0.308) 0.033 0.745
Reperfusion at day 1 − 54.236 (− 93.203 to − 15.270) − 0.333 0.007
Recanalization at day 1 − 1.606 (− 52.681–49.469) − 0.009 0.950
Volume of lesion growth is defined as the Δ baseline-day 1
WBC white blood cells
# CT: computerized tomography
*r-tPA: recombinant tissue plasminogen activator
†NIHSS: National Institutes of Health Stroke Scale
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reduction of ischemic lesion volume during the first day after
AIS and a smaller infarct volume at 90 days. According to
radiological findings, reperfusion was also associated to more
favorable prognosis in terms of good clinical response at 24 h
and good functional outcome assessed 90 days after AIS.
Noteworthy, we observed some discrepancies between recan-
alization and reperfusion rates. As compared to previous stud-
ies [17, 26], we did not observe reperfusion without
recanalization, whereas the recanalization occurred without
reperfusion in 15 patients. This implies that, in some cases,
reopening of the occluded artery is not associated with the
restoration of microcirculatory blood flow [4]. On the other
hand, it is important to emphasize that reperfusion can be non-
nutritional inducing a luxury perfusion, exceeding metabolic
demand, in non-viable tissue evolving into infarct [30] or a
deterioration of ischemic but salvageable brain tissue due to
an impairment of neurovascular unit mediated by molecular
and cellular mechanisms [31]. Nevertheless, the present study
further emphasizes a conceptual difference between reperfu-
sion and recanalization. The discrepancy between angiograph-
ically successful recanalization and non-favorable clinical out-
come might be explained by a non-visible alteration in micro-
circulation, as occurs in case of distal thrombus embolization
[6] or no-reflow phenomenon. In the latter case, swollen
Table 5 Multiple logistic regression for predicting good clinical
response at day 1 (reduction of ≥ 8 points on the NIHSS or a NIHSS
score ≤ 1), occurrence of hemorrhagic transformation and good
functional outcome (modified Rankin Scale, 0–1) at day 90
OR (95% CI) p value
Good clinical response (day 1)
Age 1.090 (1.002–1.185) 0.044
Gender, male 3.316 (0.475–23.150) 0.227
Glycemia 0.928 (0.870–0.990) 0.024
Time window to CT# 1.751 (0.108–28.333) 0.693
Intravenous r-tPA* 0.746 (0.056–9.940) 0.825
NIHSS† at onset 1.235 (0.978–1.559) 0.076
Ischemic core volume 0.946- (0.898–0.996) 0.034
Ischemic penumbra 1.002 (0.982–1.023) 0.811
Recanalization at day 1 7.721 (0.296–201.188) 0.219
Reperfusion at day 1 ≥ 75% 16.054 (1.423–181.158) 0.025
Hemorrhagic transformation (onset-day 7)
Age 1.014 (0.941–1.092) 0.720
Gender, male 0.476 (0.076–2.976) 0.427
Glycemia 1.020 (0.998–1.042) 0.076
Time window to CT 0.156 (0.007–3.573) 0.245
Intravenous r-tPA 1.197 (0.119–12.010) 0.879
NIHSS at onset 1.052 (0.862–1.284) 0.616
Ischemic core volume 1.074 (1.007–1.147) 0.030
Ischemic penumbra 1.000 (0.981–1.019) 0.984
Recanalization at day 1 0.744 (0.065–8.575) 0.812
Reperfusion at day 1 ≥ 75% 0.153 (0.022–1.047) 0.056
Good functional outcome (day 90)
Age 0.950 (0.854–1.058) 0.0.351
Gender, male 0.348 (0.035–3.471) 0.370
Glycemia 0.968 (0.939–0.998) 0.034
Time window to CT 0.071 (0.004–1.347) 0.078
Intravenous r-tPA 0.050 (0.002–1.054) 0.054
NIHSS at onset 0.734 (0.569–0.949) 0.018
Ischemic core volume 0.964 (0.922–1.007) 0.095
Ischemic penumbra 1.008 (0.985–1.032) 0.507
Recanalization at day 1 1.618 (0.178–14.700) 0.669
Reperfusion at day 1 ≥ 75% 25.801 (1.483–448.840) 0.026
WBC white blood cells
# CT: computerized tomography
*r-tPA: recombinant tissue plasminogen activator
†NIHSS: National Institutes of Health Stroke Scale
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Fig. 4 Receiver operator characteristic (ROC) curve analysis. The
predictive value of reperfusion toward good clinical response at 24 h
(a) and long-term functional outcome assessed by modified Rankin
scale (mRS) at day 90 (b)
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astrocyte, pericyte and endothelial cells determine the
narrowing of microvascular lumen and failure of microcircu-
latory reperfusion despite clot removal [32, 33]. The capillary
narrowing usually starts 1 h after AIS and contributes to brain
injury by promoting oxidative stress [32]. Not surprisingly,
more recent experimental studies [34] and clinical trials [35,
36] pointed out the role of early (or even ultra-early) reperfu-
sion as key determinant of stroke outcome [5, 37, 38]. Our
results are then consistent with previous studies based on both
CT [26] and magnetic resonance [39–41], in supporting a role
of reperfusion as surrogate marker of clinical outcome inde-
pendently of recanalization.More specifically, we emphasized
the role of earlier repeated follow-up imaging in improving
the prognostic value of reperfusion [42]. Another critical mat-
ter of discussion is the role of inflammation in ischemic/
reperfusion (I/R) injury [43]. Various studies in the last decade
emphasized the detrimental role of inflammatory response in
AIS. We previously observed that delayed rise in serum OPN
was associated with poor long-term clinical outcome after an
AIS [44]. Similarly, time-dependent changes in serum OPN
were also correlated with left-ventricular volume and function
in patients with myocardial infarction undergoing successful
reperfusion [45]. Yet, numerous clinical studies failed to dem-
onstrate any positive outcomes of anti-inflammatory strategies
in stroke patients [46]. Rather, the timing of inflammatory
response is increasingly emerging as main determinant of I/
R injury outcome. Whereas persistent inflammation exerts
negative effects on tissue repair, early inflammatory response
seems to drive tissue healing [47]. With this aim, we focused
on the early change in circulating OPN, reporting a significant
rise in reperfused patients. Nevertheless, long-term kinetic of
OPN after AIS and potential relationship with radiological
findings still remains unknown and any potential explanation
is highly speculative.
Study Limitations
Firstly, the study cohort may not be considered representative
of a general stroke population as whole and future population-
based studies are warranted to validate our results. Whereas
wewere able to demonstrate the prognostic role of reperfusion
independently of intravenous thrombolysis, our sample size
was not powerful enough to discriminate the effect of other
therapeutic approaches (i.e., intra-arterial thrombolysis and
mechanical thrombectomy). Similarly, larger studies are re-
quired to investigate the setting of minor stroke, where the
expected differences may be smaller. Secondly,
recanalization/reperfusion imaging was obtained relatively
late, and recanalization/reperfusion observed at 24 h after
AIS may not have the ability to salvage viable ischemic tissue
at risk. However, the time from admission to recanalization/
reperfusion imaging and to discharge imaging was similar for
all patients, thus not introducing a bias in the analysis. Thirdly,
the evaluation of reperfusion by CTP is incomplete because
this technique is not able to obtain metabolic information
which are crucial, in combination with hemodynamic param-
eters, to establish whether the restoration of microvascular
circulation corresponds to an actual tissue recovery or leads
to reperfusion injury [48]. In this way, only positron emission
tomography can provide both hemodynamic and metabolic
data useful to better understand tissue fate [49]. Fourthly, the
estimation of final infarct volume with 24 h NCCT could be
affected by a distortion of residual cavity due to retraction
effects related to gliosis. However, it is currently accepted that
final infarct volume is more accurately delineated in images
obtained 30 or 90 days after stroke [50]. Fifthly, it is well-
known that threshold-based fully-automated software are su-
perior to manually tracing technique we used in this study for
quantitative volumetric analysis of CBVand MTT alterations
[51]. Nevertheless, the calculation of CBV and MTT lesion
volume by a manual multi-slice planimetric method is still
considered reliable in defining core and penumbra [52] and
reperfusion on CTP [53]. Finally, different studies have de-
scribed a bi-modal delayed peak of OPN (a serum biomarker
associated with reperfusion) after AIS [54]. Therefore, future
prospective cohorts should include earlier and later time
points in order to able to correlate radiological evolution (in
terms of recanalization/reperfusion) with overtime change in
circulating OPN.
Conclusion
In conclusion, we were able to show that reperfusion occur-
ring during the first day after AIS in predicting better radio-
logical evolution of ischemic lesion and clinical outcome.
Also, reperfusion, but not recanalization was associated with
an increase in serum levels of OPN, an inflammatory mole-
cule potentially related with post-ischemic cerebral patho-
physiology. Future studies correlating radiological reperfusion
and potential biomarkers are warranted to investigate the fine-
tuned mechanisms underlying cerebral ischemia/reperfusion
salvage.
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